Risks of femoral localized periosteal thickening in patients with autoimmune inflammatory rheumatic diseases

Mod Rheumatol. 2023 Jul 4;33(4):803-810. doi: 10.1093/mr/roac062.

Abstract

Objectives: The incidence of femoral localized periosteal thickening (LPT), which can precede atypical femoral fracture (AFF), is not low (1-10%) in Japanese patients with autoimmune inflammatory rheumatic diseases (AIRDs). We explored the associations between underlying AIRDs and the prevalence of LPT.

Methods: We conducted post hoc analyses of two cohorts that included a total of 280 Japanese women, 105 of whom had AIRDs and had been taking bisphosphonate (BP) and prednisolone (PSL) and 175 of whom had rheumatoid arthritis (RA).

Results: LPT was detected in a total of 18 patients (6.4%) and 3 (1.1%) developed AFFs. RA was negatively correlated with LPT. A disease other than RA requiring glucocorticoid treatment, BP use ≥5 years, PSL use ≥7 years, and a PSL dose ≥5.5 mg/day were positively correlated with LPT. After adjusting for age, diabetes mellitus, and BP duration or daily PSL dose, RA was no longer associated with LPT.

Conclusions: LPT in Japanese patients with AIRDs was associated with BP and glucocorticoid treatment rather than underlying AIRDs. When PSL dose ≥5.5 mg/day is required long-term [typically combined with long-term BP treatment (≥5 years)], clinicians need to pay particular attention in cases LPT and AFF as well as glucocorticoid-induced osteoporosis.

Keywords: Atypical femoral fracture; autoimmune inflammatory rheumatic disease; bisphosphonate; femoral localized periosteal thickening; glucocorticoid.

MeSH terms

  • Arthritis, Rheumatoid* / diagnostic imaging
  • Arthritis, Rheumatoid* / drug therapy
  • Bone Density Conservation Agents* / therapeutic use
  • Diphosphonates / therapeutic use
  • Female
  • Femoral Fractures* / chemically induced
  • Femoral Fractures* / drug therapy
  • Femoral Fractures* / epidemiology
  • Glucocorticoids / adverse effects
  • Humans
  • Prednisolone / adverse effects

Substances

  • Bone Density Conservation Agents
  • Glucocorticoids
  • Diphosphonates
  • Prednisolone